Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers

被引:171
作者
Loo, TW
Clarke, DM
机构
[1] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Biochem, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada
关键词
D O I
10.1074/jbc.C100467200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human multidrug resistance P-glycoprotein (P-gp) interacts with a broad range of compounds with diverse structures and sizes. There is considerable evidence indicating that residues in transmembrane segments 4-6 and 10-12 form the drug-binding site. We attempted to measure the size of the drug-binding site by using thiol-specific methanethiosulfonate (MTS) cross-linkers containing spacer arms of 2 to 17 atoms. The majority of these cross-linkers were also substrates of P-gp, because they stimulated ATPase activity (2.5- to 10.1-fold). 36 P-gp mutants with pairs of cysteine residues introduced into transmembrane segments 4-6 and 10-12 were analyzed after reaction with 0.2 mm MTS cross-linker at 4 degreesC. The cross-linked product migrated with lower mobility than native P-gp in SDS gels. 13 P-gp mutants were cross-linked by MTS cross-linkers with spacer arms of 9-25 Angstrom Vinblastine and cyclosporin A inhibited crosslinking. The emerging picture from these results and other studies is that the drug-binding domain is large enough to accommodate compounds of different sizes and that the drug-binding domain is "funnel" shaped, narrow at the cytoplasmic side, at least 9-25 Angstrom in the middle, and wider still at the extracellular surface.
引用
收藏
页码:36877 / 36880
页数:4
相关论文
共 57 条
[51]   DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS [J].
SCHINKEL, AH ;
SMIT, JJM ;
VANTELLINGEN, O ;
BEIJNEN, JH ;
WAGENAAR, E ;
VANDEEMTER, L ;
MOL, CAAM ;
VANDERVALK, MA ;
ROBANUSMAANDAG, EC ;
TERIELE, HPJ ;
BERNS, AJM ;
BORST, P .
CELL, 1994, 77 (04) :491-502
[52]   ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR [J].
Senior, AE ;
Gadsby, DC .
SEMINARS IN CANCER BIOLOGY, 1997, 8 (03) :143-150
[53]   CELLULAR-LOCALIZATION OF THE MULTIDRUG-RESISTANCE GENE-PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN-TISSUES [J].
THIEBAUT, F ;
TSURUO, T ;
HAMADA, H ;
GOTTESMAN, MM ;
PASTAN, I ;
WILLINGHAM, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7735-7738
[54]   BOTH P-GLYCOPROTEIN NUCLEOTIDE-BINDING SITES ARE CATALYTICALLY ACTIVE [J].
URBATSCH, IL ;
SANKARAN, B ;
BHAGAT, S ;
SENIOR, AE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) :26956-26961
[55]   A kinetic model for the action of a resistance efflux pump [J].
Walmsley, AR ;
Zhou, TQ ;
Borges-Walmsley, MI ;
Rosen, BP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (09) :6378-6391
[56]   A GENERAL-METHOD FOR MAPPING TERTIARY CONTACTS BETWEEN AMINO-ACID-RESIDUES IN MEMBRANE-EMBEDDED PROTEINS [J].
YU, HB ;
KONO, M ;
MCKEE, TD ;
OPRIAN, DD .
BIOCHEMISTRY, 1995, 34 (46) :14963-14969
[57]   FUNCTIONAL EVIDENCE THAT TRANSMEMBRANE-12 AND THE LOOP BETWEEN TRANSMEMBRANE-11 AND TRANSMEMBRANE-12 FORM PART OF THE DRUG-BINDING DOMAIN IN P-GLYCOPROTEIN ENCODED BY MDR1 [J].
ZHANG, XP ;
COLLINS, KI ;
GREENBERGER, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (10) :5441-5448